Wincap-Plus Capsule SR is a sustained-release formulation combining Propranolol 40 mg and Flunarizine 10 mg, designed for the management of migraine prophylaxis and certain cardiovascular conditions. Propranolol, a non-selective beta-adrenergic blocker, exerts its therapeutic effect by reducing heart rate, myocardial contractility, and systemic blood pressure, thereby decreasing cardiac workload and oxygen demand. It is widely utilized in the prevention of migraine attacks, hypertension, angina pectoris, and arrhythmias. Flunarizine, a calcium channel blocker with antihistaminic properties, acts by inhibiting the influx of calcium ions into vascular smooth muscle and neuronal cells, stabilizing vascular tone and reducing neuronal excitability, which contributes to its efficacy in migraine prophylaxis and vestibular disorders. The sustained-release formulation ensures a gradual and consistent release of active ingredients, improving patient compliance by reducing dosing frequency and minimizing peak-trough fluctuations. Wincap-Plus Capsule SR should be administered under medical supervision, with caution in patients with asthma, bradycardia, hypotension, or hepatic impairment. Common adverse effects may include fatigue, dizziness, gastrointestinal disturbances, and mood changes. Contraindications include severe bradycardia, heart block, and hypersensitivity to either component. This combination therapy offers a synergistic approach to migraine prevention and cardiovascular risk management.